


CORTICOSTEROIDS




CORTICOSTEROIDS


ILOS

By the end of this lecture you will be able to:

- Revise synthesis, regulations & dysregulations of corticosteroids
- Classify available natural vs synthetic glucocorticoids; whether systemic or topical; expanding on their properties & indications
- Contrast their different ADRs & methods of prevention or treatment
- Focus on therapeutic roles of mineralocorticoids & relevant mechanism of action
- Hint on drugs antagonizing corticosteroid action



CORTICOSTEROIDS




Are a class of steroid hormones that are produced in the adrenal cortex

Glucocorticoids [GC] →

Released from Zona Fasciculata → as Cortisol, Cortisone & Corticosterone → Regulated by ACTH + cytokines (IL-1, IL-6, TNF), neuropeptides & catecholamines (stressors) Control carbohydrate, fat & protein metabolism. They are also anti-inflammatory & immunosuppressants

Mineralocorticoids [MC] → Released from Zona Glomerulosa → as Aldosterone →


Regulated by angiotensin II, potassium, and ACTH. In addition, dopamine, atrial natriuretic peptide (ANP) and other neuropeptides Control water & electrolyte homeostasis






Glucocorticoids

REGULATION





CIRCADIAN pattern of **CORTISOL** secretion





FLUID LOSS



ACTH → specifically stimulates GC & has little control over secretion of aldosterone



DYSREGULATION



Deficiency in corticosteroids → [Addison's disease]

Hyponatremia, hyperkalemia, hypoglycemia, progressive weakness & fatigue, low blood pressure, depression, anorexia & loss of weight, skin hyperpigmentation

If subjected to stresses → [Addisonian Crisis] → ↑↑ symptoms → + fever, confusion severe vomiting, diarrhea, abdominal pain & shock

Deficiency of mineralocorticoids, seldom alone → Hyponatremia, hyperkalemia, acidosis & wasting + ↓ ECF volume, hypotension & shock .

Increased production of glucocorticoids → Cushing's syndrome

Increased production of mineralocorticoids → Conn's syndrome

Hyperaldosteronism
Hypernatremia
Hypervolemia
Hypertension
Hypokalemia



PHARMACOLOGY OF EXOGENOUS GLUCOCORTICOIDS

Cortisol, Cortisone, Hydrocortisone, Prednisone, Prednisolone, Methylprednisolone, Triamcinolone, Dexamethasone, Betamethasone, Beclomethasone, Fluticasone, Budesonide, Mometasone, ...etc.

MECHANISM

GC binds to GRs 
In the cytosol
On cell membrane


1. Cytosolic GC R → mediates **GENOMIC Action** → slow process needs
→ hrs-days


Expression of proteins → Anti-inflammatory Effects

- ★ Binding & Activation
- ★ Nuclear translocation
- ★ Dimerization on GRE
- ★ Gene Transcription
- ★ mRNA Translation
- ★ New Protein Formation
e.g. Lipocortin → -ve PLA₂
-ve COX-2

Repression of proteins → Pro-inflammatory Effects


- ★ Binding & Activation
- ★ Nuclear translocation
- ★ Prevent other transcription factors (AP-1) from binding to their RE
- ★ No Gene Transcription
- ★ No mRNA Translation
- ★ No new Protein Formation e.g. No proinflammatory cytokines (IL-2) & chemokines






Inflammation occurs due to expression of proinflammatory mediators, cytokines & chemokines....etc.

INFLAMMATION




Activated GRs prevent AP-1 from binding to RE & expressing pro-inflammatory mediators, cytokines,....etc

ANTINFLAMMATORY ACTION OF GC



Activated GRs dimerize & bind to GRE allowing expression of anti-inflammatory mediators; as lipocortin, cytokines,....etc




2. Membranous GC R → mediates **NON-GENOMIC Action**

→ cross talks with GP coupled receptors → alter Ca, cAMP, their downstream kinases (PKA & PKC) → rapidly exert anti-inflammatory effects & shut down proinflammatory effects → **rapid process needs minutes-hrs**

PHARMACOLOGICAL ACTIONS = PHYSIOLOGICAL ACTION

1. On METABOLISM



CHO:

↓ glucose utilization.

↑ gluconeogenesis → hyperglycaemia

Proteins: ↓ anabolism & ↑ catabolism leading to:

Negative nitrogen balance with muscle wasting + ↑ uric a. production

Osteoporosis.

Retardation of growth in children.

Skin atrophy + capillary fragility → bruising and stria.

Fats: fat deposition on shoulders, face and abdomen.



Calcium metabolism: ↑ urinary excretion & ↓ absorption from intestine (antivitamin D action).

2. On INFLAMMATORY & IMMUNE RESPONSE

- ↓ vascular permeability; so → ↓ edema & redundancy of soft tissues
- ↓ release & synthesis of inflammatory mediators; so -ve PLA2 → -ve AA & LTs pathways....
- ↓ antigen antibody reaction → ↓ mast cell degranulation & transmitter release
- ↓ infiltration & activity of inflammatory cells (eosinophilic, lymphocytic, ...etc) by → ↓ cytokines & chemokine production
- ↓ Complement formation

3. ON HYPOTHALAMIC-PITUITARY-ADRENAL AXIS

Occurs with high doses & long periods of treatment.
Sudden withdrawal of corticosteroids →
produce a state of adrenocortical insufficiency

4. Others

Euphoria or psychotic states: may occur
(probably due to CNS electrolyte changes).



PHARMACOKINETICS

- ◆ Absorption; Most preparations are → effective orally.
Parental forms are also available.
Can get absorbed systemically when given at local sites (e.g. skin, respiratory tract, conjunctival sac, synovial spaces etc.)
- ◆ Distribution; 90% or more of cortisol in plasma is transported by reversible binding to Corticosteroids Binding Globulin (CBG) & to albumin
 - * Corticosteroids compete with each other on CBG;
Glucocorticoids bind with high affinity
Mineralocorticoids bind with low affinity
 - * Only the unbound free form is active & can enter cells by diffusion
- ◆ Metabolism; are metabolized by the liver
 - * Some preparations transform to active form in liver
 - ▶ Cortisone → Hydrocortisone
 - ▶ Prednisone → Prednisolone
- ◆ t_{1/2} is variable [short, intermediate & long acting]
Excretion; as soluble sulphates in the urine.



CLASSIFICATION ACCORDING TO $t_{1/2}$ & METHOD OF ADMINISTRATION

SYSTEMIC Drugs	Anti-inflam.	Na retention	Preparations & doses
Short Acting Preparations ($t_{1/2} < 12$ h)			
Cortisol	1	1.0	5 mg tablet 100 mg/vial (IM/IV) EMERGENCY Topical; enema
Cortisone	0.8	0.8	5 mg tablet / <i>not in liver disease</i> 25 mg/vial (IM)
Intermediate Acting Preparations ($t_{1/2} = 12$ -36 h)			
Prednisone	4	0.8	2.5, 5, 10, 20, 50 mg tablet
Prednisolone	5	0.3	5, 10 mg tablet 20 mg/vial (IM, intrarticular)
Methyl- "	5	0	0.5, 1.0 gm (IM / slow IV)
Triamcinolone	5	0	4 mg Tab., 10,40 mg/ml (IM & intrarticular)
Long Acting Preparations ($t_{1/2} > 36$ h)			
Dexamethasone [Fluorinated]	25	0	0.5 mg tab. 4mg/ml inj (IM / IV)
Betamethasone [Fluorinated]	25	0	0.5, 1 mg tab. 4mg/ml inj (IM / IV)

CLASSIFICATION ACCORDING TO $t_{1/2}$ & METHOD OF ADMINISTRATION

N.B.

Changes in basic cortisol molecule → compounds with
 ↓ mineralocorticoid activity.
 ↑ greater potency
 ↑ duration of action


INHALANT DRUGS	Administration Forms
Beclomethasone	50,100,200 mcg/md inhaler
Fluticasone	25, 50 mcg/md inhaler
Budesonide	100,200 mcg/md inhaler

TOPICAL DRUGS	Preparation	Potency
Beclomethasone	0.025 % cream	Potent
Betamethasone	0.025 & 0.12 % cream, ointment	Potent
Triamcinolone actonide	0.1 % ointment	Potent
Fluocinolone actonide	0.025% ointment	Moderate
Mometasone	0.1 % cream, ointment	Moderate
Fluticasone	0.05 % cream	Moderate
Hydrocortisone acetate	2.5 % ointment	Moderate
Hydrocortisone acetate	0.1 – 1.0% ointment	Mild

N.B. Mild-moderate topical steroids are applied on the **face as creams only**

Dosage Schedule

Time of administration of GCs → specially on prolonged use → follows natural circadian rhythm i.e. early morning → to minimize hypothalamo-pituitary-adrenal axis impairment. Better if administered on alternate days



INDICATIONS

HORMONE REPLACEMENT THERAPY



Emergency situation

- ◆ Parental **Cortisol (hydrocortisone)** → 100 mg IV / every 6-8 hrs until patient is stable. Dose → gradually reduced → reach maintenance dosage in 5 dys
- ◆ Fluids and electrolytes should be corrected.
- ◆ Treatment of precipitating factors.

- ◆ **Cortisol** (20-30 mg/day orally) + (**fludrocortisone** (0.1 mg orally)
- ◆ **Dexamethasone** could be given on prolonged use
- ◆ Doses must be increased in stress to prevent development of Addisonian crisis
- ◆ Doses should follow circadian rhythm

In Diagnoses → **Dexamethasone suppression test**

In Treatment → **Cortisol**; Temporally administred AFTER surgical removal of pituitary / adrenal / corticosteroid secreting tumors

1. ADRENAL INSUFFECIENCY ACUTE & Chronic

Addisonian Crisis

Addison's Disease

2. CUSHING'S SYNDROME

INDICATIONS

→ I. ANTI-INFLAMMATORY & IMMUNOSUPPRESSANT

- ◆ Severe allergic reactions e.g. serum sickness, angioneurotic edema... etc.
- ◆ Diseases of allergic origin; bronchial asthma, rhinitis, conjunctivitis, eczema & many other atopic & proliferative skin diseases
- ◆ Autoimmune disorders; rheumatoid arthritis, inflammatory bowel disease systemic lupus erythrematosus, nephrotic syndrome,...
- ◆ Organ transplantation; kidney, cardiac, bone marrow (↓rejection)
- ◆ Blood dyscrasias; hemolytic anemia, thrombocytopenic purpura, agranulocytosis ... etc.
- ◆ Acute gout (resistant) to other drugs

Prednisolone
Dexamethasone
Betamethasone

> Anti-inflammatory & Immunosuppression


INDICATIONS

II. OTHERS

Dexamethasone
Betamethasone


- ◆ Raised intracranial pressure
- ◆ In neoplastic diseases
 - With cytotoxic drugs → as in Hodgkin's disease, acute lymphocytic leukaemia
 - 1^{ry} or 2^{ndry} neoplasms in the brain & postoperative to brain surgery → ↓ edema
 - In antiemetic regimens → prevent / cure emesis of chemotherapy
- ◆ Suppress excess ACTH production

If water retention is undesirable



1. ADRs

SUPPRESSION OF HYPOTHALAMIC PITUITARY ADRENAL AXIS




HOW TO AVOID →




Withdraw Corticosteroids Regimens

- ◆ If < than 1 w. & not used in big doses no fear.
If big dose you may ↓ 2.5-5 mg prednisolone → at an interval of 2-3 days
- ◆ If longer periods & high dose
↓ halve dose weekly until 25 mg prednisolone or equivalent is reached
Then ↓ by about 1mg every 3-7 days.

IATROGENIC CUSHING'S SYNDROME



2. ADRs



If possible → slow withdraw to allow body to slowly resume its normal balance of ACTH & cortisol

If not possible to stop because of underlying disease → ↓ treat concurrent symptom separately

- * Antidiabetic for hyperglycaemia
- * Bisphosphonates for osteoporosis
- * H₂ blocker or proton pump inhibitors for peptic ulcer

3. ADRs

- ◆ Hyperglycemia , glycosuria, diabetes mellitus > fluorinated preparations
- ◆ Growth retardation → premature closure of epiphysis → short stature
- ◆ Muscle wasting → -ve nitrogen balance > fluorinated preparations
- ◆ Fat redistribution & abnormal deposition
- ◆ Hypertension, oedema, Na retention
- ◆ Hypokalaemia
- ◆ Osteoporosis → -ve of osteoblasts / +ve osteoclasts & ↓ Ca absorption, ↑ Ca excretion → vertebral compression & fractures
- ◆ Avascular necrosis of head of femur ? Coagulation / apoptosis?
- ◆ Menstrual irregularities
- ◆ Psychiatric disorders; depression, euphoria,...
- ◆ Impairment of defense mechanism → serious infections, flare of dormant T.B., activate hepatitis, ↑ reaction to live vaccines
- ◆ Delayed wound healing
- ◆ Peptic ulcer specially if with NSAIDs
- ◆ Skin, acne, striae, hirsutism
- ◆ Ocular toxicity → glaucoma & cataract



Local Toxicity

- ◆ Skin → infection, atrophy, bruising.
- ◆ Eye → viral infection, cataract, glaucoma.
- ◆ Inhalation → fungal infection, hoarseness
- ◆ Intrarticular → infection, necrosis

CONTRAINDICATIONS

- ◆ Diabetes mellitus.
- ◆ Hypertension or heart failure
- ◆ History of mental disorders or Epilepsy.
- ◆ Osteoporosis
- ◆ Peptic ulcer
- ◆ Presence of infection or Tuberculosis → requires chemotherapy before administration

Precautions

- ◆ Patients receiving GCs and is subjected to stress → double the dose
- ◆ In children receiving → take care of live attenuated vaccines
- ◆ In pregnant women; better avoid fluorinated GCs → teratogenicity
- ◆ Neo-born to mothers taking high dose GCs → -ve HPA axis



PHARMACOLOGY OF MINERALOCORTICOCORTICIDS

MECHANISM

Aldosterone, Deoxycorticosterone, Fludrocortisone

Bind to mineralocorticoid receptors [MC R] \Rightarrow in **MC responsive cells** i.e. **distal nephron**

Binds GC > MC

GC is destroyed, enzymatically in MC responsive cells \Rightarrow so MC will bind to its receptor alone without any competition from GC.


1. **Cytosolic MC R** \rightarrow mediates **GENOMIC Action** \rightarrow Expression of proteins

In distal & collecting tubules

- ◆ Na pumps \rightarrow \uparrow Na retention
- ◆ Na channels \rightarrow \uparrow Na reuptake from lumen
- ◆ K simporters \rightarrow \uparrow excretion of K & H

N.B. Actions also on (colon, sweat & salivary glands)

2. **Membranous GC R** \rightarrow mediates **NON-GENOMIC Action**



Interact with GP coupled receptors & channels to mediate **rapid adaptive changes to fluid depletion**

EFFECTS / USES / PREPARATIONS

Net effect is to conserve body sodium → osmotic effect → water follows
 → expansion of extracellular fluid
 ↑ renal excretion of potassium & ↓ intracellular potassium

In excess → hypertension, atherosclerosis, fibrosis → vascular & cardiac remodeling → cerebral hemorrhage / stroke & or cardiomyopathy

SYSTEMIC Drugs	Anti-inflam.	Na retention	Preparations & doses
Aldosterone	0.3	3000	Natural / Not used clinical
Deoxycortone sterone[DOCA]	0	100	2.5 mg sublingual, ineffective orally ? Inactive in liver
Fludrocortisone	10	150	100mcg oral tablets / duration of 36-72hrs / Drug of Choice in Replacement Therapy

PHARMACOLOGY OF CORTICOSTEROID ANTAGONIST

Medications that inhibit adrenal steroid synthesis to ↓ GC

MITOTANE

-ve 11 β -hydroxylase

↓ Corticosteroid production → ↓ its peripheral metabolism & plasma & urine levels

Used in Cushing syndrome; whether iatrogenic, or to alleviate severe symptoms till removal by surgery

Safe in pregnancy

Medications that compete with steroids on receptors to block MC actions

SPIRONOLACTONE

Is a competitive aldosterone antagonist →

Is a K⁺ sparing diuretic (weak, slow onset & prolonged effect)

Used in hypertension (alternation with others), in heart failure

In Hyperaldosteronism (Conn's)

CORTICOSTEROIDS

КОРТИКОСТЕРОИДЫ

9002 240K

